Not recruiting
Non-small cell lung cancer
Not recruitingStudy on Datopotamab Deruxtecan and Osimertinib for Patients with Advanced Non-Small Cell Lung Cancer After Osimertinib Treatment
Registered drugNo placebo
Study on Datopotamab Deruxtecan and Osimertinib for Patients with Advanced Non-Small Cell Lung Cancer After Osimertinib Treatment
Registered drugNo placebo
- Disease:Non-small cell lung cancer
- Substances:CarboplatinCisplatin+3
Countries:
Belgium
Belgium- Participants:18–64 years · 65+ years
- Substances:Carboplatin



